A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Pfizer

Status: Completed

Conditions: Metastatic Breast Cancer

Treatments: Drug: palbociclib

Study type: Observational

Funder types: Industry

Identifiers

NCT04671615

NCT04671615 (Registry Identifier)

A5481160

Details and patient eligibility

About

The purpose of this study is to understand the treatment patterns, patients and their clinical outcomes in a real life setting in Israel. This study was done in adult breast cancer patients who have started palbociclib combination treatment as per the national basket of health services in January 2018 until August 2020 for all lines of therapy.

This study had included adult patients who were prescribed with palbociclib for their breast cancer which had spread to other parts of the body.

Patients are followed for around 3.5 years.

Enrollment: 559 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A diagnosis of metastatic breast cancer, based on the National/MHS cancer registry.
• Newly diagnosed metastatic breast cancer patients and newly treated with palbociclib within 6 months of diagnosis, in any line of treatment in the metastatic setting.
• Available data on palbociclib treatment for at least 6 months.
• Continuous healthcare plan enrolment in MHS for at least one year before index date.

Exclusion criteria

• Patients that initiated HER2 inhibitors.

Trial design

559 participants in 1 patient group

Patients with metastatic, HR+/HER2- breast cancer.

Description:

Patients who initiated first or subsequent lines of treatment with palbociclib

Treatment:

Drug: palbociclib